Market Research Logo

Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016

Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016’, provides an overview of the Crohn's Disease (Regional Enteritis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Crohn's Disease (Regional Enteritis)
  • The report reviews pipeline therapeutics for Crohn's Disease (Regional Enteritis) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Crohn's Disease (Regional Enteritis) therapeutics and enlists all their major and minor projects
  • The report assesses Crohn's Disease (Regional Enteritis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Crohn's Disease (Regional Enteritis)
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Crohn's Disease (Regional Enteritis)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Crohn's Disease (Regional Enteritis) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Crohn's Disease (Regional Enteritis) Overview
Therapeutics Development
Crohn's Disease (Regional Enteritis) - Therapeutics under Development by Companies
Crohn's Disease (Regional Enteritis) - Therapeutics under Investigation by Universities/Institutes
Crohn's Disease (Regional Enteritis) - Pipeline Products Glance
Crohn's Disease (Regional Enteritis) - Products under Development by Companies
Crohn's Disease (Regional Enteritis) - Products under Investigation by Universities/Institutes
Crohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics Development
Crohn's Disease (Regional Enteritis) - Therapeutics Assessment
Drug Profiles
Crohn's Disease (Regional Enteritis) - Dormant Projects
Crohn's Disease (Regional Enteritis) - Discontinued Products
Crohn's Disease (Regional Enteritis) - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Crohn's Disease (Regional Enteritis), H2 2016
Number of Products under Development for Crohn's Disease (Regional Enteritis) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Investigation by Universities/Institutes, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by 4D Pharma Plc, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by 4SC AG, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by AB Science SA, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by AbbVie Inc, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Alfa Wassermann S.p.A, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Alteogen Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Amgen Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by ARA Healthcare Pvt. Ltd., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Arena Pharmaceuticals, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Astellas Pharma Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by BioLingus AG, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Bionovis SA, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by BioTherapeutics Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Calypso Biotech SA, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Celgene Corporation, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by ChemoCentryx, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by ChironWells GmbH, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by CLL Pharma, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Coherus BioSciences, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Commence Bio, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by DBV Technologies S.A., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Eisai Co., Ltd., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Eli Lilly and Company, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Enterome Bioscience SA, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Enzo Biochem, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Ferring International Center S.A., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Galapagos NV, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Genentech, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Genor BioPharma Co., Ltd., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Gilead Sciences, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by iCo Therapeutics Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Idera Pharmaceuticals, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Immune Response BioPharma, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Innovent Biologics, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Johnson & Johnson, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Jyant Technologies, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Kang Stem Biotech Co., Ltd., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by KPI Therapeutics, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by MedImmune, LLC, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Merck & Co., Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Mesoblast Limited, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Mycenax Biotech Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Neovacs SA, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Oncobiologics, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Oncodesign SA, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by OSE Immunotherapeutics, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Pfenex Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Pfizer Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Pieris Pharmaceuticals, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Pluristem Therapeutics Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Qu Biologics Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Re-Pharm Limited, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by RedHill Biopharma Ltd., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Sandoz International GmbH, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by SATT North SAS, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Second Genome, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Selexys Pharmaceuticals Corporation, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Selvita S.A., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Shire Plc, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Sigmoid Pharma Limited, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Soligenix, Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Stelic Institute & Co., Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Sylentis S.A.U., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Therapeutic Proteins International, LLC, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Tiziana Life Sciences Plc, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Trino Therapeutics Limited, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by TxCell SA, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Ventria Bioscience, H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Virobay Inc., H2 2016
Crohn's Disease (Regional Enteritis) - Pipeline by Xbrane Biopharma AB, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Crohn's Disease (Regional Enteritis) - Dormant Projects, H2 2016
Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..1), H2 2016
Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..2), H2 2016
Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..3), H2 2016
Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..4), H2 2016
Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..5), H2 2016
Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..6), H2 2016
Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..7), H2 2016
Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..8), H2 2016
Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..9), H2 2016
Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..10), H2 2016
Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..11), H2 2016
Crohn's Disease (Regional Enteritis) - Discontinued Products, H2 2016
Crohn's Disease (Regional Enteritis) - Discontinued Products (Contd..1), H2 2016
List of Figures
Number of Products under Development for Crohn's Disease (Regional Enteritis), H2 2016
Number of Products under Development for Crohn's Disease (Regional Enteritis) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report